QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.013540v1 68/3/616    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rothem, L. Articles by Assaraf, Y. G. Search for Related Content PubMed PubMed Citation Articles by Rothem, L. Articles by Assaraf, Y. G.

The Reduced Folate Carrier Gene Is a Novel Selectable Marker for Recombinant Protein Overexpression

Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel (L.R., B.B., M.S., Y.G.A.); and Department of Rheumatology, Vrije Universiteit University Medical Center, Amsterdam, the Netherlands (G.J.)

Folate cofactors are one-carbon donors essential for the biosynthesis of purines and thymidylate. Mammalian cells are devoid of folate biosynthesis and are therefore folate auxotrophs that take up folate vitamins primarily via the reduced folate carrier (RFC). In this study, we showed that the human RFC (hRFC) gene can serve as a novel selectable marker for the overproduction of recombinant proteins. Toward this end, a hemagglutinin (HA) epitope tagged hRFC (hRFC-HA) was introduced into a bicistronic vector (pIRES2-EGFP), upstream of an enhanced green fluorescent protein (EGFP) reporter gene. Chinese hamster ovary cells deficient in RFC activity were isolated and transfected with this construct, followed by gradual deprivation of leucovorin, the sole folate source in the growth medium. Only cells with hRFC-HA overexpression were able to take up leucovorin and thereby survive these selective conditions. Western blot and immunofluorescence analyses confirmed that the hRFC-HA was overexpressed at extremely high levels, properly glycosylated and sorted out to the plasma membrane. This resulted in a 450-fold increase in [³H]methotrexate influx and 100-fold increased sensitivity to methotrexate, relative to untransfected RFC-deficient cells. Flow cytometric analysis consistently revealed that EGFP was overexpressed 100-fold above the autofluorescence level. Overproduction of hRFC-HA and EGFP was stably maintained for at least 2 months in a constant concentration of leucovorin. These results establish a novel RFC-based metabolic selection system for the efficient overexpression of recombinant proteins. Furthermore, the possible implications to subcellular transporter localization and restoration of MTX sensitivity in drug-resistant tumors by RFC-based gene therapy are discussed.

Address correspondence to: Dr. Yehuda G. Assaraf, Department of Biology, Technion-Israel Institute of Technology, Haifa 32000, Israel. E-mail: assaraf{at}tx.technion.ac.il

This article has been cited by other articles:

				I. Lasry, B. Berman, R. Straussberg, Y. Sofer, H. Bessler, M. Sharkia, F. Glaser, G. Jansen, S. Drori, and Y. G. Assaraf A novel loss-of-function mutation in the proton-coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for function Blood, September 1, 2008; 112(5): 2055 - 2061. [Abstract] [Full Text] [PDF]

				I. Ifergan, G. Jansen, and Y. G. Assaraf The Reduced Folate Carrier (RFC) Is Cytotoxic to Cells under Conditions of Severe Folate Deprivation: RFC AS A DOUBLE EDGED SWORD IN FOLATE HOMEOSTASIS J. Biol. Chem., July 25, 2008; 283(30): 20687 - 20695. [Abstract] [Full Text] [PDF]